Paradigm Biopharmaceuticals Ltd has released a press release.
A paradigm shift in treating osteoarthritis pain
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Appendix 4E and 2017 Annual Report
- Paradigm (PAR) - First Ross River Trial Participant Treated
- Paradigm To Commence Phase 2 Ross River Virus Clinical Trial
- Paradigm Enters Heart Failure Market
- Hay Fever Trial Update
Later from Paradigm Biopharmaceuticals
- Paradigm Phase 2 Ross River Virus Clinical Trial Update
- PARs Osteoarthritis Phase 2 Receives Ethics Approval
- PAR reports pain reduction in 83% of osteoarthritis patients
- First Participant Dosed in PARs Phase 2b OA Clinical Trial
- PAR Successfully Completes A$5.75m Placement
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals